Cargando…

Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study

Primary sclerosing cholangitis (PSC) is frequently associated with pruritus, which significantly impairs quality of life. Maralixibat is a selective ileal bile acid transporter (IBAT) inhibitor that lowers circulating bile acid (BA) levels and reduces pruritus in cholestatic liver diseases. This is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bowlus, Christopher L., Eksteen, Bertus, Cheung, Angela C., Thorburn, Douglas, Moylan, Cynthia A., Pockros, Paul J., Forman, Lisa M., Dorenbaum, Alejandro, Hirschfield, Gideon M., Kennedy, Ciara, Jaecklin, Thomas, McKibben, Andrew, Chien, Elaine, Baek, Marshall, Vig, Pamela, Levy, Cynthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187837/ https://www.ncbi.nlm.nih.gov/pubmed/37184523 http://dx.doi.org/10.1097/HC9.0000000000000153

Ejemplares similares

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
por: Mayo, Marlyn J., et al.
Publicado: (2019)

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
por: Eksteen, Bertus, et al.
Publicado: (2020)

Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study
por: Loomes, Kathleen M., et al.
Publicado: (2022)

PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)
por: Stinton, Laura M., et al.
Publicado: (2014)

The immunobiology of primary sclerosing cholangitis
por: Aron, Jonathan H., et al.
Publicado: (2009)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Maralixibat: First Approval
por: Shirley, Matt
Publicado: (2021)

The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population
por: Toy, Elaine, et al.
Publicado: (2011)

Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis
por: Chen, Yung-Yi, et al.
Publicado: (2019)

Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
por: Sclair, Seth N, et al.
Publicado: (2015)

Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management
por: Milkiewicz, Piotr, et al.
Publicado: (2020)

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
por: Chapman, Michael Huw, et al.
Publicado: (2019)

Correction to: Maralixibat: First Approval
por: Shirley, Matt
Publicado: (2021)

Human β-Defensin 2 in Primary Sclerosing Cholangitis
por: Chang, Cindy, et al.
Publicado: (2017)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Hepatic Endothelial CCL25 Mediates the Recruitment of CCR9(+) Gut-homing Lymphocytes to the Liver in Primary Sclerosing Cholangitis
por: Eksteen, Bertus, et al.
Publicado: (2004)

Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis
por: Ludwig, Daniel R., et al.
Publicado: (2022)

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis
por: Borchers, Andrea T., et al.
Publicado: (2009)

Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis
por: Onofrio, Fernanda, et al.
Publicado: (2023)

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Quality of life in primary sclerosing cholangitis: a systematic review
por: Marcus, Elena, et al.
Publicado: (2021)

Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis
por: Fischer, Sandra, et al.
Publicado: (2014)

A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis
por: Gindin, Yevgeniy, et al.
Publicado: (2021)

Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma
por: González, Marisol I., et al.
Publicado: (2022)

Gene Expression by PBMC in Primary Sclerosing Cholangitis: Evidence for Dysregulation of Immune Mediated Genes
por: Aoki, Christopher A., et al.
Publicado: (2006)

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis–Inflammatory Bowel Disease
por: Chung, Brian K., et al.
Publicado: (2018)

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis
por: Tanaka, Atsushi
Publicado: (2019)

NLRP3 receptor contributes to protection against experimental antigen-mediated cholangitis
por: González, Marisol Ibet, et al.
Publicado: (2020)

Primary sclerosing cholangitis.
por: Spence, R. A., et al.
Publicado: (1984)

Primary sclerosing cholangitis
por: Worthington, Joy, et al.
Publicado: (2006)

A210 HEPATOLITHIASIS IS A FREQUENT AND PROGNOSTIC FINDING IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
por: Jubran, B, et al.
Publicado: (2022)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Primary sclerosing cholangitis and pregnancy
por: Kammeijer, Casper Q., et al.
Publicado: (2011)

Sclerosing Cholangitis in Behçet's Disease
por: Ben Slama Trabelsi, Aida, et al.
Publicado: (2013)

An Overview on Primary Sclerosing Cholangitis
por: Vlăduţ, Cătălina, et al.
Publicado: (2020)

Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency
por: Zhao, Xueheng, et al.
Publicado: (2022)

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
por: Goode, Elizabeth C., et al.
Publicado: (2019)

A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale
por: Levy, Cynthia, et al.
Publicado: (2018)

Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
por: Buness, Cynthia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mccdh3vhtu5rdqv6c6qv8u5868